TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 18.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,700 shares of the biopharmaceutical company’s stock after selling 3,659 shares during the period. J.W. Cole Advisors Inc.’s holdings in TG Therapeutics were worth $279,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in TGTX. Vanguard Group Inc. raised its position in shares of TG Therapeutics by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock valued at $233,500,000 after acquiring an additional 199,770 shares in the last quarter. Wellington Management Group LLP raised its position in shares of TG Therapeutics by 1.4% during the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock valued at $53,627,000 after acquiring an additional 43,290 shares in the last quarter. Opaleye Management Inc. raised its position in shares of TG Therapeutics by 2.9% during the 1st quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock valued at $34,679,000 after acquiring an additional 65,000 shares in the last quarter. Hood River Capital Management LLC acquired a new stake in shares of TG Therapeutics during the 1st quarter valued at approximately $22,420,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of TG Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,896 shares of the biopharmaceutical company’s stock valued at $19,333,000 after acquiring an additional 19,214 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TGTX has been the topic of several research reports. The Goldman Sachs Group upped their price target on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. B. Riley upped their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Trading Up 0.7 %

NASDAQ:TGTX opened at $25.25 on Thursday. TG Therapeutics, Inc. has a 1 year low of $6.46 and a 1 year high of $26.41. The stock has a market cap of $3.90 billion, a price-to-earnings ratio of 109.78 and a beta of 2.21. The business has a fifty day moving average of $21.84 and a 200-day moving average of $18.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. During the same quarter in the prior year, the business posted ($0.34) earnings per share. The company’s revenue for the quarter was up 357.0% compared to the same quarter last year. Equities analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.